CSS
TRDA icon

Cubist Systematic Strategies’s Entrada Therapeutics TRDA Stock Holding History

Cubist Systematic Strategies’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$712K Buy
+122,676
New +$718K ﹤0.01% 2112
2023
Q2 		– Sell
-4,160
Closed -$60.3K – 4304
2023
Q1 		$60.3K Buy
4,160
+3,755
+927% +$50.1K ﹤0.01% 3535
2022
Q4 		$5.48K Sell
405
-600
-60% -$10.5K ﹤0.01% 4086
2022
Q3 		$16K Sell
1,005
-869
-46% -$11K ﹤0.01% 4252
2022
Q2 		$23K Buy
+1,874
New +$14.2K ﹤0.01% 4197
2022
Q1 		– Sell
-11,090
Closed -$190K – 3776
2021
Q4 		$190K Buy
+11,090
New +$269K ﹤0.01% 3049

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Cubist Systematic Strategies's TRDA Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Entrada Therapeutics (TRDA) in Q3 2025: 122,676 shares worth $712K. The stake represents ﹤0.01% of the portfolio and ranks #2112 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in TRDA as recently as Q1 2023.

Cubist Systematic Strategies first reported a position in TRDA in Q4 2021 and has held it in 6 quarters since. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Cubist Systematic Strategies held 122,676 shares of Entrada Therapeutics worth $712K as of Q3 2025.
  • Entrada Therapeutics was a new Cubist Systematic Strategies position in Q3 2025.
  • Entrada Therapeutics made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2112 holding.
  • Cubist Systematic Strategies first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.